Literature DB >> 31305861

Chemokine Receptor Expression Pattern Correlates to Progression of Conjunctival Melanocytic Lesions.

Jolique A van Ipenburg1, Nadine E de Waard2, Nicole C Naus3, Martine J Jager2, Dion Paridaens3,4, Robert M Verdijk1,4,5.   

Abstract

Purpose: Chemokines play a role in the progression and metastatic spread of both cutaneous and uveal melanomas. The aim of this study was to examine the prognostic value of expression of chemokine receptors CCR7, CXCR4, and CCR10 in conjunctival melanocytic lesions.
Methods: In total, 44 conjunctival nevi, 21 cases of primary acquired melanosis (PAM) with atypia and 35 conjunctival melanomas, were included. After immunohistochemical staining for CCR7, CXCR4, and CCR10 the immunoreactive score (IRS) was determined. The findings were correlated for association with melanoma and development of metastasis. For mechanistic evaluation, we used a mouse melanoma metastasis model using two human conjunctival melanoma cell lines, CM2005.1 and CRMM1.
Results: All tested chemokines showed a significantly higher expression in conjunctival melanoma than conjunctival nevi. There was a statistically significant difference between the IRS in nevi and PAM with atypia for nuclear IRS in CCR10 (P = 0.03) and both nuclear and cytoplasmic IRS in CXCR4 (P < 0.01 and P = 0.03, respectively); this was also true evaluating the groups PAM with atypia and melanoma all together (P < 0.01). Furthermore, a trend for lower IRS was seen in cases of melanoma without metastasis, with a suggestive pattern of a higher IRS in cases that did develop metastases, supported for CXCR4 using the mouse melanoma metastasis model. Conclusions: Expression of specific chemokines changes during the progression and metastatic spread of conjunctival melanocytic lesions. Differential chemokine profiles may hold prognostic value for patients with conjunctival melanomas and might be considered as a therapeutic target.

Entities:  

Year:  2019        PMID: 31305861     DOI: 10.1167/iovs.19-27162

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  4 in total

Review 1.  Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies.

Authors:  Anastasia Gkiala; Sotiria Palioura
Journal:  Clin Ophthalmol       Date:  2020-10-09

2.  Identification of Early-Onset Metastasis in SF3B1 Mutated Uveal Melanoma.

Authors:  Wojtek Drabarek; Job van Riet; Josephine Q N Nguyen; Kyra N Smit; Natasha M van Poppelen; Rick Jansen; Eva Medico-Salsench; Jolanda Vaarwater; Frank J Magielsen; Tom Brands; Bert Eussen; Thierry P P van den Bosch; Robert M Verdijk; Nicole C Naus; Dion Paridaens; Annelies de Klein; Erwin Brosens; Harmen J G van de Werken; Emine Kilic
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

3.  CXCR4, CXCR5 and CD44 May Be Involved in Homing of Lymphoma Cells into the Eye in a Patient Derived Xenograft Homing Mouse Model for Primary Vitreoretinal Lymphoma.

Authors:  Neele Babst; Lisa K Isbell; Felix Rommel; Aysegul Tura; Mahdy Ranjbar; Salvatore Grisanti; Cordula Tschuch; Julia Schueler; Soroush Doostkam; Peter C Reinacher; Justus Duyster; Vinodh Kakkassery; Nikolas von Bubnoff
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

4.  Screening of Biological Target Molecules Related to Glucocorticoid-Induced Cataract (GIC) on the Basis of Constructing ceRNA Network.

Authors:  Zhan Shi; Xiumei Zhao; Ying Su; Chao Wang; Ping Liu; Hongyan Ge
Journal:  Biochem Genet       Date:  2021-06-02       Impact factor: 1.890

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.